Brief: Annexin Pharmaceuticals: ANXV Boosts Retinal Perfusion In RVO, DR Patients
23/06/2026 07:34
BRIEF-Annexin Pharmaceuticals: ANXV Boosts Retinal Perfusion In RVO, DR Patients June 23 (Reuters) - Annexin Pharmaceuticals AB (publ) ANNX.ST:
ANXV TREATMENT IMPROVES RETINAL CAPILLARY PERFUSION IN RVO AND DR PATIENTS IN NEXUS STUDY
RESULTS THUS FAR SUPPORT FURTHER CLINICAL DEVELOPMENT OF ANXV IN RVO AND DR
Source text: ID:nMFN2T49Lp
Further company coverage: ANNX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Annexin Pharmaceuticals AB (publ)
See all newsBrief: Annexin Pharmaceuticals Q3 Net Loss At SEK 9.5 Mln
Brief: Annexin Pharmaceuticals Q2 2026 Net Loss SEK 11.6 Mln
Brief: Annexin Pharmaceuticals Gets International Nonproprietary Name Drug Candidate Anxv
Brief: Annexin Pharmaceuticals Updates On Nine Patients Treated In Nexus Study
Brief: Annexin's Rights Issue 98% Subscribed